RecruitingPhase 1NCT06442761
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- St. Jude Children's Research Hospital
- Principal Investigator
- Alexis Leonard, MD, MD, MPHSt. Jude Children's Research Hospital
- Intervention
- Motixafortide(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (2)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Collaborators
Ayrmid Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06442761 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi